David Friedman - Morgan Stanley
Maybe we can start quickly with AP, the spasticity drug. You guys had positive Phase II data there and a slightly different population, so for people that may or may not have been following along with this program, can you just briefly describe what types of data you are looking to generate out of the Phase III program, and whether you see a lot of risk going from spinal cord injury to MS, or is spasticity given the underlying pathology.
I think most experts in the field would say that spasticity response to treatment independent of the original [neurology] of the spasticity, whether it's spinal cord, whether it's MS stroke or traumatic brain injury, and there are differences in the patient population, the spinal cord injury population, typically that's had spasticity for longer.
Multiple sclerosis patients obviously lot of things going with their disease progression, and it's the reason why we really took pretty stringent requirements of patient selection that's taken us while to recruit the right patients. We're requiring certain minimal level of spasticity, minimal level of disability and a maximum level of disability. We are looking at the spasticity to measurement of what's called the Ashworth Score.
Read the rest of this transcript for free on seekingalpha.com